Press Releases

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,799 restricted...

– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 –...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,533 restricted...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 800 restricted...

– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million,...

-- Conference Call Scheduled for Monday, November 3, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 27, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage...

– Transactions Provide Karyopharm with $100 Million of Financial Flexibility and Additional Capital – – Preliminary Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue for the...